Drug Trial Radar · NCT07074236
Pharmacokinetics and Pharmacodynamics Study
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 2025
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.
Conditions
- Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Interventions
QLC7401 injectionDrug
QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.
RBD7022 injectionDrug
RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
- AUCTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
- TmaxTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
- t1/2Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
- CL/FTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
- VZ/FTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University.
Qingdao, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.